论文部分内容阅读
1965年发现色甘酸钠,这在哮喘病的防治方面无疑是一个重大进展。该药与支气管扩张药不同,它不具有支气管扩张作用,也不能对抗组胺和SRS-A等过敏介质的作用,亦不影响抗原和抗体的结合,但是预先用药可以防止哮喘的速发反应和迟发反应。其作用机理一般认为是通过抑制肺组织肥大细胞的磷酸二酯酶,升高细胞内的cAMP含量而稳定肥大细胞的细胞膜,使钙离子不易进入细胞内,从而防止肥大细胞脱颗粒和释放过敏介质。色甘酸钠对过敏性哮喘的良好预防作用引
The discovery of cromolyn in 1965 was undoubtedly a significant advance in the prevention and treatment of asthma. The drug is different from bronchodilators, it does not have bronchodilator effects, it can not fight histamine and SRS-A and other allergic mediators, nor does it affect the binding of antigens and antibodies, but the pre-medication can prevent the rapid onset of asthma and Delayed reaction. Its mechanism of action is generally believed that by inhibiting the phosphorylated diesterase in mast cells of the lung tissue, increasing intracellular cAMP content and stabilizing the cell membrane of mast cells, so that calcium ions are not easy to enter the cell, thus preventing mast cells degranulation and release of allergic mediators . Cromolyn sodium in the prevention of allergic